株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

特殊医薬品業界:2011年動向

Specialty Pharmaceutical Industry - 2011 Yearbook

発行 GBI Research 商品コード 200296
出版日 ページ情報 英文 168 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GBI Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
特殊医薬品業界:2011年動向 Specialty Pharmaceutical Industry - 2011 Yearbook
出版日: 2011年05月24日 ページ情報: 英文 168 Pages
概要

特殊医薬品市場には、加齢性黄斑変性症、注意欠陥多動性障害、アルツハイマー病、緑内障、HIV/AIDS、てんかん、関節リウマチ、結腸直腸癌などの適応が含まれます。これらの疾患は、モニタリング、診断、治療において医師の特別な注意が必要です。また薬剤には特別なインフラとベンダーによる注意が必要となります。

当レポートでは、特殊医薬品業界の概要と疾患別の概要、市場の特性とともに、臨床開発中の有望薬剤パイプライン動向をまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 特殊医薬品業界の2011年動向イントロダクション

第3章 HIV/AIDS治療薬市場

  • 疾患概要
  • 市場概要
  • 市場の特性
    • 市場予測
    • 年間治療費
    • 治療形態
    • 地域別分布
  • 促進因子と阻害因子

第4章 加齢性黄斑変性症

  • 疾患概要
  • 市場概要
  • 市場の特性
    • 市場予測
    • 年間治療費
    • 治療形態
    • 地域別分布
  • 促進因子と阻害因子

第5章 注意欠陥多動性障害

  • イントロダクション
  • 市場の特性
    • 市場予測
    • 年間治療費
    • 治療形態
    • 地域別分布
  • 促進因子と阻害因子

第6章 アルツハイマー病

  • イントロダクション
  • 市場の特性
    • 市場予測
    • 年間治療費
    • 治療形態
    • 地域別分布
  • 促進因子と阻害因子

第7章 結腸直腸癌

  • イントロダクション
  • 市場の特性
    • 市場予測
    • 年間治療費
    • 治療形態
    • 地域別分布
  • 促進因子と阻害因子

第8章 関節リウマチ

  • イントロダクション
  • 市場の特性
    • 市場予測
    • 年間治療費
    • 治療形態
    • 地域別分布
  • 促進因子と阻害因子

第9章 てんかん

  • イントロダクション
  • 市場の特性
    • 市場予測
    • 年間治療費
    • 治療形態
    • 地域別分布
  • 促進因子と阻害因子

第10章 緑内障

  • イントロダクション
  • 市場の特性
    • 市場予測
    • 年間治療費
    • 治療形態
    • 地域別分布
  • 促進因子と阻害因子

第11章 パイプライン分析

第12章 戦略的統合

  • 合併買収
  • ライセンシング契約
  • 共同開発契約

第13章 付録

目次
Product Code: GBIHC078MR

Abstract

Summary

GBI Research' s “Specialty Pharmaceutical Industry - 2011 Yearbook” essentially provides insights on specialty pharmaceutical sales and price forecasts until 2017. The report provides in-depth therapeutics analysis of eight niche indications, namely: Human Immunodeficiency Virus (HIV)/Acquired immune deficiency syndrome (AIDS), age related macular degenerative disorders, attention deficit hyperactivity disorder (ADHD), Alzheimer' s disease, colorectal cancer, rheumatoid arthritis, epilepsy and glaucoma, including their annual cost of therapy (ACT) and revenue. In addition, the geographical distribution of these disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the specialty pharmaceutical Research and Development (R&D) pipeline and the potential future blockbusters up to 2017. Furthermore, it also covers the market forecasts and treatment usage patterns of these eight therapeutic indications up to 2017. Finally, the key trend analysis on Mergers and Acquisitions (M&A), licensing agreements and co-development deals involving specialty pharmaceuticals is also presented.

Scope

The report covers:

  • Annualized market data for the specialty pharmaceutical market from 2001 to 2009, with forecasts to 2017.
  • Market analysis for the eight major indications in the global specialty pharmaceutical market which includes HIV/AIDS, age related macular degenerative disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer' s disease, colorectal cancer, rheumatoid arthritis, epilepsy and glaucoma.
  • Data and analysis on the specialty pharmaceutical market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Key M&A activities and licensing agreements that took place from 2004 to 2010 in the specialty pharmaceutical market.

Reasons To Buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to:

  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Executive Summary

GBI Research, the leading business intelligence provider has released its latest research “Specialty Pharmaceutical Industry - 2011 Yearbook”, which essentially provides insights on specialty pharmaceutical sales and price forecasts until 2017. The report provides in-depth therapeutics analysis of eight niche indications, namely: Alzheimer' s disease, attention deficit hyperactivity disorder (ADHD), colorectal cancer, epilepsy, glaucoma, Human Immunodeficiency Virus (HIV)/Acquired immune deficiency syndrome (AIDS), macular degeneration and rheumatoid arthritis, including their annual cost of therapy (ACT) and revenue. In addition, the geographical distribution of these disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the specialty pharmaceutical Research and Development (R&D) pipeline and the potential future blockbusters up to 2017. Furthermore, it also covers the market forecasts and treatment usage patterns of these eight therapeutic indications up to 2017. Finally, the key trend analysis on Mergers and Acquisitions (M&A), licensing agreements and co-development deals involving specialty pharmaceuticals is also presented.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research' s team of industry experts.

HIV/AIDS and Rheumatoid Arthritis are the Major Indications, Which Will Drive the Specialty Pharmaceutical Market in the Future

Specialty Pharmaceutical Market, Market Share of Major Indications, 2009

Source: GBI Research

The Specialty pharmaceutical market is dominated by rheumatoid arthritis and HIV/AIDS in the year 2009. Rheumatoid arthritis accounted for 26% of the total market, while HIV/AIDS closely followed it with a market share of 25%. Alzheimer' s disease, Attention Deficit Hyperactive Disorder (ADHD) and epilepsy have also shown strong market presence, holding shares of 14%, 8% and 7% respectively in 2009.

The global HIV/AIDS market has witnessed a strong growth over the past few years. According to GBI Research analysis, the market is estimated to grow at a steady rate of 3% between 2009 and 2017. Increased disease awareness levels have increased treatment seeking and diagnosed populations in the US, Europe and Japan. Furthermore the progress in HIV treatment and introduction of Highly Active Antiretroviral Therapy (HAART) and other effective drugs have contributed effectively to the market growth.

On the other hand the global rheumatoid arthritis market also has recorded a strong growth over the past few years. GBI Research forecasts the market to grow at a better compound annual growth rate (CAGR) of 8.6% between 2009 and 2017. The major drivers for the growth of the rheumatoid arthritis therapeutics market are the increase in the incidence rate and prevalence rate. The introduction of state-of-the-art diagnostic tools to detect rheumatoid arthritis at an early stage is another factor that will be driving the growth of this market.

In addition age related macular degeneration market has grown historically at high growth rate and it is expected to grow at approximately 10% between 2009 and 2017. Increasing diseased population and diagnosis rates are the major drivers of the market growth.

Strong Product Pipeline will Drive the Specialty Pharmaceutical Market

The specialty pharmaceutical market pipeline for the eight conditions has 2,800 molecules in the collective pipeline. The pipeline is active with many new promising molecules and it is dominated by colorectal cancer, followed by Glaucoma and Alzheimer' s disease.

The pipeline consists of the many novel promising molecules that are expected to support the drug in future for many of the indications. The small and niche markets such as the Glaucoma and Alzheimer' s disease have recently been in focus for many pharmaceutical companies.

Strategic Consolidations Have Led to the Entry of New Players in the Specialty Pharmaceutical Market

In the past five to six years many pharmaceutical companies have improved their product profiles with respect to the specialty pharmaceutical market. This is due to strategic deals with the aim of introducing new products with better efficacy and safety profiles into the market. Many pharmaceutical companies have acquired or signed licensing and co-development deals with companies possessing potential products for different indications in the Specialty pharmaceutical segment. The acquisition of Wyeth Pharmaceuticals by Pfizer, and the acquisition of ID Biomedical by GlaxoSmithKline were the major acquisitions in the Specialty pharmaceutical market. Under licensing agreements one of the important deals was a licensing agreement between DiaGenic and Pfizer to develop a biomarker for early stages of Alzheimer' s disease. In addition, Trimeris and F.Hoffmann-La-Roche have entered into a licensing agreement with Novartis to sell Novartis' s branded drug Fuzeon. In addition to these, a large number of co-development deals took place with respect to HIV/AIDS and Alzheimer' s disease therapeutics in the past five to six years.

These strategic consolidations will help the acquirer and licensee companies to diversify their profiles by entering and expanding their presence in the Specialty pharmaceutical market, which will in turn make the market more competitive. These consolidations will also help the companies to generate revenues, thereby increasing the total revenue of the global Specialty pharmaceutical market.

Decline in the Alzheimer' s Disease Therapeutics Market Could Restrict the Growth of Specialty Pharmaceutical Market

The decline in the Alzheimer' s disease market, which is the third largest market in the Specialty pharmaceutical segment, will affect the growth of specialty pharmaceutical market in the future. GBI Research analysis shows that the global Alzheimer' s disease (AD) therapeutics market is expected to decline at a CAGR of 3% by the year 2017. The market structure is projected to change in the near future following the patent expiry of the leading drugs in the next two to three years. The next couple of years will witness major products going off-patent leading to a flood of generics into the market. Aricept, the most popular drug in this market will lose its patent protection in 2010, which will affect the entire market. The flood of generics will lead to a price decline which will restrict market growth.

Table of Contents

1. Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Specialty Pharmaceutical Market - 2011 Yearbook: Introduction

  • 2.1. Scope
  • 2.2. GBI Research Report Guidance

3. Specialty Pharmaceutical Market - 2011 Yearbook: HIV Therapeutics Market

  • 3.1. Disease Overview
  • 3.2. Market Overview
  • 3.3. Global HIV Therapeutics Market: Market Characterization
    • 3.3.1. Market Forecasts
    • 3.3.2. Annual Cost of Therapy
    • 3.3.3. Usage Patterns
    • 3.3.4. Geographical Distribution
  • 3.4. HIV Therapeutics Market: Drivers and Restraints
    • 3.4.1. Market Drivers
    • 3.4.2. Market Restraints

4. Specialty Pharmaceutical Market - 2011 Year Book: Age Related Macular Degenerative Disorder

  • 4.1. Disease Overview
  • 4.2. Market Overview
  • 4.3. Age Related Macular Degenerative Disorder: Market Characterization
    • 4.3.1. Market Forecasts
    • 4.3.2. Geographical Distribution
    • 4.3.3. Annual Cost of Therapy
    • 4.3.4. Usage Patterns
  • 4.4. Age Related Macular Degenerative Disorder: Drivers and Restraints
    • 4.4.1. Market Drivers
    • 4.4.2. Market Restraints

5. Specialty Pharmaceutical Market - 2011 Yearbook: Attention Deficit Hyperactive Disorder (ADHD)

  • 5.1. Introduction
  • 5.2. Attention Deficit Hyperactive Disorder: Market Characterization
    • 5.2.1. Market Forecasts
    • 5.2.2. Geographical Distribution
    • 5.2.3. Annual Cost of Therapy
    • 5.2.4. Usage Patterns
  • 5.3. Attention Deficit Hyperactive Disorder Market: Drivers and Restraints
    • 5.3.1. Market Drivers
    • 5.3.2. Market Restraints

6. Specialty Pharmaceutical Market - 2011 Yearbook: Alzheimer' s Disease

  • 6.1. Introduction
  • 6.2. Alzheimer' s disease: Market Characterization
    • 6.2.1. Market Forecasts
    • 6.2.2. Geographical Distribution
    • 6.2.3. Annual Cost of Therapy
    • 6.2.4. Usage Patterns
  • 6.3. Alzheimer' s Disease Market: Drivers and Restraints
  • 6.4. Market Drivers
  • 6.5. Market Restraints

7. Specialty Pharmaceutical Market - 2011 Yearbook: Colorectal Cancer

  • 7.1. Introduction
  • 7.2. Colorectal Cancer: Market Characterization
    • 7.2.1. Market Forecasts
    • 7.2.2. Geographical Distribution
    • 7.2.3. Annual Cost of Therapy
    • 7.2.4. Usage Patterns
  • 7.3. Colorectal Cancer Market: Drivers and Restraints
    • 7.3.1. Market Drivers
    • 7.3.2. Market Restraints

8. Specialty Pharmaceutical Market - 2011 Yearbook: Rheumatoid Arthritis

  • 8.1. Introduction
  • 8.2. Rheumatoid Arthritis: Market Characterization
    • 8.2.1. Market Forecasts
    • 8.2.2. Annual Cost of Therapy
    • 8.2.3. Treatment Usage Patterns
    • 8.2.4. Geographical Distribution
  • 8.3. Rheumatoid Arthritis Market: Drivers and Restraints
    • 8.3.1. Market Drivers
    • 8.3.2. Market Restraints

9. Specialty Pharmaceutical Market - 2011 Yearbook: Epilepsy

  • 9.1. Introduction
  • 9.2. Epilepsy: Market Characterization
    • 9.2.1. Market Forecasts
    • 9.2.2. Geographical Distribution
    • 9.2.3. Annual Cost of Therapy
    • 9.2.4. Usage Patterns
  • 9.3. Epilepsy Market: Drivers and Restraints
    • 9.3.1. Market Drivers
    • 9.3.2. Market Restraints

10. Specialty Pharmaceutical Market - 2011 Yearbook: Glaucoma

  • 10.1. Introduction
  • 10.2. Glaucoma: Market Characterization
    • 10.2.1. Market Forecasts
    • 10.2.2. Geographical Distribution
    • 10.2.3. Annual Cost of Therapy
    • 10.2.4. Usage Patterns
  • 10.3. Glaucoma Market: Drivers and Restraints
    • 10.3.1. Drivers of the Glaucoma Market
    • 10.3.2. Barriers for the Glaucoma Market

11. Specialty Pharmaceutical Market - 2011Yearbook: Pipeline Analysis

  • 11.1. Specialty Pharmaceutical Pipeline: HIV market
  • 11.2. Molecule Profile for Promising Drugs under Clinical Development: HIV
    • 11.2.1. Rilpivirine hydrochloride (TMC278)
    • 11.2.2. Elvitegravir
    • 11.2.3. Elvitegravir/GS-9350/Emtricitabine/Tenofovir (Quad)
    • 11.2.4. Racivir
    • 11.2.5. Apricitabine (ATC)
    • 11.2.6. Tesamorelin
  • 11.3. Specialty Pharmaceutical Pipeline: Age Related Macular Degeneration
  • 11.4. Molecule Profile for Promising Drugs under Clinical Development: Age Related Macular Degeneration
    • 11.4.1. VEGF Trap-Eye
  • 11.5. Specialty Pharmaceutical Pipeline: Attention Deficit Hyperactive Disorder
  • 11.6. Molecule Profile for Promising Drugs under Clinical Development: Attention Deficit Hyperactive Disorder
    • 11.6.1. ABT-894 (Sofinicline)
    • 11.6.2. Eltoprazine
    • 11.6.3. AZD3480 (TC-1734) (Isopronicline)
  • 11.7. Specialty Pharmaceutical Pipeline: Alzheimer' s Disease
  • 11.8. Molecular Profile for the Promising Drugs under Clinical Development: Alzheimer' s Disease
    • 11.8.1. Bapineuzumab
    • 11.8.2. Gammagard
    • 11.8.3. Dimebon
    • 11.8.4. Rember (Trx0014) (methylthionium chloride)
  • 11.9. Specialty Pharmaceutical Pipeline: Colorectal Cancer
  • 11.10. Molecule Profile for Promising Drugs under Clinical Development: Colorectal Cancer
    • 11.10.1. Aflibercept
    • 11.10.2. Brivanib
    • 11.10.3. OncoVAX
    • 11.10.4. TroVax
    • 11.10.5. KRX-0401 (Perifosine)
  • 11.11. Specialty Pharmaceutical Pipeline: Rheumatoid Arthritis
  • 11.12. Profiles for Promising Drugs under Clinical Development: Rheumatoid Arthritis
    • 11.12.1. T-614 (iguratimod)
    • 11.12.2. CP-690550
    • 11.12.3. Arzerra (HuMax-CD20 /Ofatumumab)
    • 11.12.4. VX-509
  • 11.13. Specialty Pharmaceutical Pipeline: Epilepsy
  • 11.14. Molecule Profile for Promising Drugs under Clinical Development: Epilepsy
    • 11.14.1. Stedesa (Eslicarbazepine Acetate)
    • 11.14.2. Comfyde (Carisbamate)
    • 11.14.3. Retigabine
    • 11.14.4. Brivaracetam
    • 11.14.5. Ganaxolone
    • 11.14.6. E2007 (Perampanel)
  • 11.15. Specialty Pharmaceutical Pipeline: Glaucoma
  • 11.16. Molecule Profile for Promising Drugs under Clinical Development: Glaucoma
    • 11.16.1. Tafluprost (Saflutan)
    • 11.16.2. NCX-116 (Formerly PF-03187207)

12. Specialty Pharmaceutical Market - 2011 Yearbook: Strategic Consolidations

  • 12.1. Mergers and Acquisitions
    • 12.1.1. Pfizer
    • 12.1.2. F. Hoffmann-La Roche
    • 12.1.3. GlaxoSmithKline
  • 12.2. Licensing Deals
    • 12.2.1. Pfizer
    • 12.2.2. F. Hoffmann-La Roche
    • 12.2.3. GlaxoSmithKline
  • 12.3. Co-Development Deals
    • 12.3.1. Pfizer
    • 12.3.2. F. Hoffmann-La Roche
    • 12.3.3. GlaxoSmithKline

13. Specialty Pharmaceutical Market - 2011 Yearbook: Appendix

  • 13.1. Market Definitions
  • 13.2. Abbreviations
  • 13.3. Research Methodology
    • 13.3.1. Coverage
    • 13.3.2. Secondary Research
    • 13.3.3. Primary Research
    • 13.3.4. Forecasts
    • 13.3.5. Expert Panel Validation
  • 13.4. Contact Us
  • 13.5. Disclaimer
  • 13.6. Sources

List of Tables

  • Table 1: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Revenue ($m), 2001 - 2009
  • Table 2: Specialty Pharmaceutical Market, HIV Market, Global, Revenue ($m), 2009 - 2017
  • Table 3: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009
  • Table 4: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2017
  • Table 5: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Usage Patterns, 2001 - 2009
  • Table 6: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Usage Patterns, 2001 - 2009
  • Table 7: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Market Size ($m), by countries, 2001-2009
  • Table 8: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Market Size ($m), by countries, 2009-2017
  • Table 9: HIV Therapeutics Market, Global, Key Drugs Going Off Patent, 2008 - 2016
  • Table 10: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Revenue ($m), 2001-2009
  • Table 11: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Revenue ($m), 2009-2017
  • Table 12: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Geographical Distribution of Revenues , 2001 - 2009
  • Table 13: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Geographical Distribution of Revenues, 2010 - 2017
  • Table 14: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Annual Cost of Therapy ($), 2001-2009
  • Table 15: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Annual Cost of Therapy ($), 2009-2017
  • Table 16: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Usage Patterns, 2001 - 2009
  • Table 17: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Usage Patterns, 2009 - 2017
  • Table 18: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Revenue ($m), 2001-2009
  • Table 19: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Revenue ($m), 2009-2017
  • Table 20: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Geographical Distribution of Revenues ($m), 2001 - 2009
  • Table 21: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Geographical Distribution of Revenues ($m), 2009 - 2017
  • Table 22: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Annual Cost of Therapy ($), 2001-2009
  • Table 23: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Annual Cost of Therapy ($), 2009-2017
  • Table 24: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Usage Patterns, 2001 - 2009
  • Table 25: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Usage Patterns, 2009 - 2017
  • Table 26: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Revenue ($m), 2001-2009
  • Table 27: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Revenue ($m), 2009-2017
  • Table 28: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Geographical Distribution of Revenues ($m), 2001 - 2009
  • Table 29: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Geographical Distribution of Revenues ($m), 2009 - 2017
  • Table 30: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Annual Cost of Therapy ($), 2001-2009
  • Table 31: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Annual Cost of Therapy ($), 2009-2017
  • Table 32: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Usage Patterns, 2001 - 2009
  • Table 33: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Usage Patterns, 2009 - 2017
  • Table 34: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Revenue ($m), 2001-2009
  • Table 35: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Revenue ($m), 2009-2017
  • Table 36: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Geographical Distribution of Revenues ($m), 2001 - 2009
  • Table 37: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Geographical Distribution of Revenues ($m), 2009 - 2017
  • Table 38: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Annual Cost of Therapy ($), 2001-2009
  • Table 39: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Annual Cost of Therapy ($), 2009-2017
  • Table 40: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Usage Patterns, 2001 - 2009
  • Table 41: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Usage Patterns, 2009 - 2017
  • Table 42: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Revenue ($m), 2001-2009
  • Table 43: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Revenue ($m), 2009-2017
  • Table 44: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2001-2009
  • Table 45: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2009-2017
  • Table 46: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Usage Patterns, 2001 - 2009
  • Table 47: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Usage Patterns, 2009 - 2017
  • Table 48: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Geographical Distribution of Revenues ($m), 2001 - 2009
  • Table 49: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Geographical Distribution of Revenues ($m), 2009 - 2017
  • Table 50: Specialty Pharmaceutical Market, Epilepsy, Global, Revenue ($m), 2001-2009
  • Table 51: Specialty Pharmaceutical Market, Epilepsy, Global, Revenue ($m), 2009-2017
  • Table 52: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 2001 - 2009
  • Table 53: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 2009 - 2017
  • Table 54: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2001-2009
  • Table 55: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2009-2017
  • Table 56: Specialty Pharmaceutical Market, Epilepsy, Global, Usage Patterns, 2001 - 2009
  • Table 57: Specialty Pharmaceutical Market, Epilepsy, Global, Usage Patterns, 2009 - 2017
  • Table 58: Specialty Pharmaceutical Market, Glaucoma, Global, Revenue ($m), 2001-2009
  • Table 59: Specialty Pharmaceutical Market, Glaucoma, Global, Revenue ($m), 2009-2017
  • Table 60: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 2001 - 2009
  • Table 61: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 2009 - 2017
  • Table 62: Specialty Pharmaceutical Market, Glaucoma, Global, Annual Cost of Therapy ($), 2001-2009
  • Table 63: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2009-2017
  • Table 64: Specialty Pharmaceutical Market, Glaucoma, Global, Usage Patterns, 2001 - 2009
  • Table 65: Specialty Pharmaceutical Market, Glaucoma, Global, Usage Patterns, 2009 - 2017
  • Table 66: Specialty Pharmaceutical Market, M&A, Pfizer, 2004 to 2010
  • Table 67: Specialty Pharmaceutical Market, M&A, F. Hoffmann-La Roche, 2004 to 2010
  • Table 68: Specialty Pharmaceutical Market, M&A, GlaxoSmithKline, 2004 to 2010
  • Table 69: Specialty Pharmaceutical Market, Licensing Deals, Pfizer, 2004 to 2010
  • Table 70: Specialty Pharmaceutical Market, Licensing Deals , F. Hoffmann-La Roche, 2004 to 2010
  • Table 71: Specialty Pharmaceutical Market, Licensing Deals, GlaxoSmithKline, 2004 to 2010
  • Table 72: Specialty Pharmaceutical Market, Co-development Deals, Pfizer, 2004-2010
  • Table 73: Specialty Pharmaceutical Market, Co-development Deals, F. Hoffmann-La Roche, 2004-2010
  • Table 74: Specialty Pharmaceutical Market, Co-development Deals, GlaxoSmithKline, 2004-2010

List of Figures

  • Figure 1: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Market Size ($m), 2001-2017
  • Figure 2: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2017
  • Figure 3: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Usage Patterns, 2000 - 2016
  • Figure 4: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Diseased Population, 2001 - 2017
  • Figure 5: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Treatment Seeking Population, 2001 - 2017
  • Figure 6: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Diagnosis Population, 2000 - 2016
  • Figure 7: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Prescription Population, 2000 - 2016
  • Figure 8: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Revenue ($m), 2001 - 2017
  • Figure 9: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Revenue ($bn), 2001-2017
  • Figure 10: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Geographical Distribution of Revenues ($bn), 2001 - 2017
  • Figure 11: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Annual Cost of Therapy ($), 2001-2017
  • Figure 12: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Usage Patterns, 2000 - 2017
  • Figure 13: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Diseased Population, 2001 - 2017
  • Figure 14: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Treatment Seeking Population, 2001 - 2017
  • Figure 15: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Diagnosis Population, 2001 - 2017
  • Figure 16: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Prescription Population, 2001 - 2017
  • Figure 17: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Revenue ($bn), 2001-2017
  • Figure 18: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Geographical Distribution of Revenues ($bn), 2001 - 2017
  • Figure 19: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Annual Cost of Therapy ($), 2001-2017
  • Figure 20: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Usage Patterns, 2001 - 2017
  • Figure 21: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Diseased Population, 2001 - 2017
  • Figure 22: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Treatment Seeking Population, 2001 - 2017
  • Figure 23: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Diagnosis Population, 2001 - 2017
  • Figure 24: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Prescription Population, 2001 - 2017
  • Figure 25: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Revenue ($bn), 2001-2017
  • Figure 26: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Geographical Distribution of Revenues ($bn), 2001 - 2017
  • Figure 27: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Annual Cost of Therapy ($), 2001-2017
  • Figure 28: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Usage Patterns, 2001 - 2017
  • Figure 29: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Diseased Population, 2001 - 2017
  • Figure 30: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Treatment Seeking Population, 2001 - 2017
  • Figure 31: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Diagnosis Population, 2001 - 2017
  • Figure 32: Specialty Pharmaceutical Market, Alzheimer' s Disease, Global, Prescription Population, 2001 - 2017
  • Figure 33: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Revenue ($bn), 2001-2017
  • Figure 34: Specialty Pharmaceutical Market Colorectal Cancer, Global, Geographical Distribution of Revenues ($bn), 2001 - 2017
  • Figure 35: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Annual Cost of Therapy ($), 2001-2017
  • Figure 36: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Usage Patterns, 2001 - 2017
  • Figure 37: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Diseased Population, 2001 - 2017
  • Figure 38: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Treatment Seeking Population, 2001 - 2017
  • Figure 39: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Diagnosis Population, 2001 - 2017
  • Figure 40: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Prescription Population, 2001 - 2017
  • Figure 41: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Revenue ($bn), 2001-2017
  • Figure 42: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2001-2017
  • Figure 43: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Usage Patterns, 2001 - 2017
  • Figure 44: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Diseased Population, 2001 - 2017
  • Figure 45: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Treatment Seeking Population, 2001 - 2017
  • Figure 46: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Diagnosis Population, 2001 - 2017
  • Figure 47: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Prescription Population, 2001 - 2017
  • Figure 48: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Geographical Distribution of Revenues ($bn), 2001 - 2017
  • Figure 49: Specialty Pharmaceutical Market, Epilepsy, Global, Revenue ($bn), 2001-2017
  • Figure 50: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($bn), 2001 - 2017
  • Figure 51: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2001-2017
  • Figure 52: Specialty Pharmaceutical Market, Epilepsy, Global, Usage Patterns, 2001 - 2017
  • Figure 53: Specialty Pharmaceutical Market, Epilepsy, Global, Diseased Population, 2001 - 2017
  • Figure 54: Specialty Pharmaceutical Market, Epilepsy, Global, Treatment Seeking Population, 2001 - 2017
  • Figure 55: Specialty Pharmaceutical Market, , Epilepsy, Global, Diagnosis Population, 2001 - 2017
  • Figure 56: Specialty Pharmaceutical Market, Epilepsy, Global, Prescription Population, 2001 - 2017
  • Figure 57: Specialty Pharmaceutical Market, Glaucoma, Global, Revenue ($bn), 2001-2017
  • Figure 58: Specialty Pharmaceutical Market, Glaucoma, Global, Geographical Distribution of Revenues ($bn), 2001 - 2017
  • Figure 59: Specialty Pharmaceutical Market, Glaucoma, Global, Annual Cost of Therapy ($), 2001-2017
  • Figure 60: Specialty Pharmaceutical Market, Glaucoma, Global, Usage Patterns, 2001 - 2017
  • Figure 61: Specialty Pharmaceutical Market, Glaucoma, Global, Diseased Population, 2001 - 2017
  • Figure 62: Specialty Pharmaceutical Market, Glaucoma, Global, Treatment Seeking Population, 2001 - 2017
  • Figure 63: Specialty Pharmaceutical Market, Glaucoma, Global, Diagnosis Population, 2001 - 2017
  • Figure 64: Specialty Pharmaceutical Market, Glaucoma, Global, Prescription Population, 2001 - 2017
  • Figure 65: Specialty Pharmaceutical Market, Pipeline, Indication, 2010
  • Figure 66: Specialty Pharmaceutical Market, Pipeline, Phase Analysis, 2010
  • Figure 67: Specialty Pharmaceutical Market, Pipeline, By Indication, 2010
  • Figure 68: Specialty Pharmaceutical Market, Pipeline, HIV, 2010
  • Figure 69: Specialty Pharmaceutical Market, Pipeline, Age Related Macular Degeneration, 2010
  • Figure 70: Specialty Pharmaceutical Market, Pipeline Attention Deficit Hyperactive Disorder, 2010
  • Figure 71: Specialty Pharmaceutical Market, Pipeline, Alzheimer' s Disease, 2010
  • Figure 72: Specialty Pharmaceutical Market, Pipeline, Colorectal Cancer, 2010
  • Figure 73: Specialty Pharmaceutical Market, Pipeline, Rheumatoid Arthritis, 2010
  • Figure 74: Specialty Pharmaceutical Market, Pipeline, Epilepsy, 2010
  • Figure 75: Specialty Pharmaceutical Market, Pipeline, Glaucoma, 2010
  • Figure 76: Specialty Pharmaceutical Market, M&A, Year on Year, 2004 to 2010
  • Figure 77: Specialty Pharmaceutical Market, M&A, By Indication, 2004 to 2010
  • Figure 78: Specialty Pharmaceutical Market, M&A, Deal Type, 2004 to 2010
  • Figure 79: Specialty Pharmaceutical Market, Licensing Deals, Year on Year, 2004 to 2010
  • Figure 80: Specialty Pharmaceutical Market, Licensing Deals, By Indication, 2004 to 2010
  • Figure 81: Specialty Pharmaceutical Market, Co-development Deals, Year on Year, 2004 to 2010
  • Figure 82: Specialty Pharmaceutical Market, Co-development Deals, By Indication, 2004 to 2010
  • Figure 83: GBI Research Market Forecasting Model
Back to Top